株式会社極東書店トップ > 商品一覧 > Behavioral Pharmacology of Neuropeptides: Oxytocin.
商品詳細
Behavioral Pharmacology of Neuropeptides: Oxytocin.
・ISBN 978-3-319-63738-9 hard EUR 229.99
¥61,475.- (税込) ※(※)価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。
| 著者・編者 | Hurlemann, Rene / Grinevich, Valery (eds.), |
|---|---|
| シリーズ | (Current Topics in Behavioral Neurosciences) |
| 出版社 | (Springer International Publishing AG, SZ) |
| 出版年月 | 2018 |
| ページ数 | 593 pp. |
| 言語 | ENG |
| ニュース番号 | <A02-32207> |
解説
This volume collects cutting-edge expert reviews in the oxytocin field and will be of interest to a broad scientific audience ranging from social neuroscience to clinical psychiatry. The role of the neuropeptide oxytocin in social behaviors is one of the earliest and most significant discoveries in social neuroscience. Influential studies in animal models have delineated many of the neural circuits and genetic components that underlie these behaviors. These discoveries have inspired researchers to investigate the effects of oxytocin on brain and behavior in humans and its potential relevance as a treatment for psychiatric disorders including borderline personality disorder and autism and schizophrenia spectrum disorders. In fact, there is no established social psychopharmacology in Psychiatry, and oxytocin can be seen as the first endogenous agent specifically addressing social-cognitive impairment in psychiatric disorders, with animal research suggesting that it could be especiallyefficient in the early postnatal period. From a human perspective, it is crucial to understand more precisely who can benefit from potential oxytocin-related treatments, which outcome measures will best represent their effects, how they should be administered, and what brain mechanisms are likely involved in mediating their effects. This type of "precision medicine" approach is in line with the research domain criteria defined by the U.S. National Institute of Mental Health.